PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 178 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2015. The put-call ratio across all filers is 1.04 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $768,012 | -21.7% | 25,033 | +2.2% | 0.01% | -16.7% |
| Q2 2023 | $981,074 | -2.2% | 24,484 | -0.4% | 0.01% | -14.3% |
| Q1 2023 | $1,003,436 | +6.1% | 24,588 | +0.4% | 0.01% | 0.0% |
| Q4 2022 | $945,366 | -28.0% | 24,485 | -0.8% | 0.01% | -30.0% |
| Q3 2022 | $1,313,000 | -7.6% | 24,676 | +1.2% | 0.01% | 0.0% |
| Q2 2022 | $1,421,000 | -26.5% | 24,380 | -3.8% | 0.01% | -9.1% |
| Q1 2022 | $1,933,000 | +19.5% | 25,332 | -5.8% | 0.01% | +37.5% |
| Q4 2021 | $1,618,000 | +5.2% | 26,885 | -2.1% | 0.01% | 0.0% |
| Q3 2021 | $1,538,000 | -10.7% | 27,460 | -3.2% | 0.01% | +33.3% |
| Q2 2021 | $1,722,000 | -13.8% | 28,379 | -0.4% | 0.01% | -14.3% |
| Q1 2021 | $1,997,000 | +15.9% | 28,496 | -1.0% | 0.01% | +16.7% |
| Q4 2020 | $1,723,000 | -1.3% | 28,790 | -0.8% | 0.01% | -25.0% |
| Q3 2020 | $1,745,000 | +13.5% | 29,032 | -1.0% | 0.01% | +14.3% |
| Q2 2020 | $1,538,000 | +62.2% | 29,316 | +3.7% | 0.01% | +40.0% |
| Q1 2020 | $948,000 | -29.5% | 28,261 | -4.7% | 0.01% | 0.0% |
| Q4 2019 | $1,344,000 | +17.0% | 29,662 | -1.7% | 0.01% | 0.0% |
| Q3 2019 | $1,149,000 | +2.5% | 30,189 | +17.1% | 0.01% | +25.0% |
| Q2 2019 | $1,121,000 | +15.8% | 25,787 | +1.3% | 0.00% | 0.0% |
| Q1 2019 | $968,000 | -14.3% | 25,445 | -3.1% | 0.00% | -20.0% |
| Q4 2018 | $1,130,000 | -13.1% | 26,269 | -0.8% | 0.01% | +25.0% |
| Q3 2018 | $1,301,000 | +56.2% | 26,472 | +1.8% | 0.00% | +33.3% |
| Q2 2018 | $833,000 | +5.2% | 25,994 | +2.3% | 0.00% | 0.0% |
| Q1 2018 | $792,000 | -34.4% | 25,418 | -4.0% | 0.00% | -25.0% |
| Q4 2017 | $1,208,000 | +22.1% | 26,470 | +0.5% | 0.00% | +33.3% |
| Q3 2017 | $989,000 | -15.0% | 26,346 | +8.1% | 0.00% | -25.0% |
| Q2 2017 | $1,163,000 | +15.6% | 24,376 | +10.5% | 0.00% | 0.0% |
| Q1 2017 | $1,006,000 | +48.6% | 22,060 | +5.3% | 0.00% | +33.3% |
| Q4 2016 | $677,000 | -99.9% | 20,957 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $718,996,000 | +1.6% | 21,011 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $707,622,000 | -42.0% | 20,979 | -9.0% | 0.00% | -40.0% |
| Q1 2016 | $1,221,000,000 | -31.5% | 23,057 | -0.7% | 0.01% | -28.6% |
| Q4 2015 | $1,782,000,000 | +178815.7% | 23,215 | -4.2% | 0.01% | +75.0% |
| Q3 2015 | $996,000 | -99.9% | 24,222 | -7.7% | 0.00% | -42.9% |
| Q2 2015 | $1,856,541,000 | -26.2% | 26,252 | -7.2% | 0.01% | -30.0% |
| Q1 2015 | $2,514,544,000 | +3.8% | 28,301 | +3.5% | 0.01% | 0.0% |
| Q4 2014 | $2,423,344,000 | -11.7% | 27,333 | -3.5% | 0.01% | -16.7% |
| Q3 2014 | $2,744,678,000 | +1.8% | 28,319 | -3.5% | 0.01% | 0.0% |
| Q2 2014 | $2,696,734,000 | +58.9% | 29,357 | +21.1% | 0.01% | +50.0% |
| Q1 2014 | $1,697,118,000 | +32.6% | 24,248 | +8.9% | 0.01% | +33.3% |
| Q4 2013 | $1,279,727,000 | +20.8% | 22,260 | +1.0% | 0.01% | 0.0% |
| Q3 2013 | $1,059,706,000 | +183.1% | 22,037 | +70.7% | 0.01% | +200.0% |
| Q2 2013 | $374,332,000 | – | 12,908 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |